Northwest Biotherapeutics plans to submit MAA for DCVax-L treatment

Northwest Biotherapeutics plans to submit a Marketing Authorization Application in the U.K., to the Medicines and Healthcare Products Regulatory Agency for commercial approval of the Company’s DCVax-L treatment for glioblastoma. The Company believes that it has now completed all of the remaining prerequisites for such an application, including certain steps related to implementation of the approved Pediatric Investigation Plan and submission of the required formal notification to the MHRA of the upcoming MAA. As the Company reported in its recent 10-Q filing, the Company is in the final stages of completing the application package itself. The Company anticipates submitting the MAA in approximately the next 30-45 days. The Company plans to request that the MHRA review the MAA under the 150-business day process that the MHRA has established to accelerate the availability of new medicines for patients in the U.K.